Quantification of rifampicin and rifabutin in plasma of tuberculosis patients by micellar liquid chromatography
Impacte
Scholar |
Altres documents de l'autoria: Goberna Bravo, Mª Angeles; Durgbanshi, Abhilasha; Bose, Devasish; Mishra, Pooja; Albiol Chiva, Jaume; Esteve-Romero, Josep; Vives-Peris, Vicente
Metadades
Mostra el registre complet de l'elementcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/7013
comunitat-uji-handle3:10234/8638
comunitat-uji-handle4:
INVESTIGACIONAquest recurs és restringit
https://doi.org/10.1016/j.microc.2020.104865 |
Metadades
Títol
Quantification of rifampicin and rifabutin in plasma of tuberculosis patients by micellar liquid chromatographyAutoria
Data de publicació
2020Editor
ElsevierISSN
0026-265XCita bibliogràfica
BRAVO, Maria Ángeles Goberna, et al. Quantification of Rifampicin and Rifabutin in Plasma of Tuberculosis Patients by Micellar Liquid Chromatography. Microchemical Journal, 2020, p. 104865.Tipus de document
info:eu-repo/semantics/articleVersió de l'editorial
https://www.sciencedirect.com/science/article/pii/S0026265X20307165Versió
info:eu-repo/semantics/publishedVersionParaules clau / Matèries
Resum
A Micellar Liquid Chromatographic method is described to determine Rifampicin and Rifabutin in plasma from
Tuberculosis patients. Samples were diluted in mobile phase and then directly injected, avoiding long and ... [+]
A Micellar Liquid Chromatographic method is described to determine Rifampicin and Rifabutin in plasma from
Tuberculosis patients. Samples were diluted in mobile phase and then directly injected, avoiding long and tedious extraction steps. The analytes were resolved from the matrix without interferences from endogenous
compounds using a mobile phase of sodium dodecyl sulfate 0.15 mol L-1–6%(v/v) 1-pentanol and phosphate
buffer at pH 3, running at 1 mL min−1 through a C18 column at 25 °C. Detection was carried out by UV
absorbance at 270 nm. Under these conditions, the final chromatographic analysis time was 22 min. The analytical methodology was validated following the FDA 2018 Bioanalytical Method Validation Guidance for
Industry. The response of the drugs in plasma was linear in the 0.05–5 μg/mL range, with r
2 > 0.9993. Trueness
and precision were <14% for both substances. Carry over and matrix effects were negligible. Dilution integrity,
robustness and stability were also investigated. Method was reliable, economic, eco-friendly, safe, easy-toconduct, and with a high sample throughput, thus useful for routine analysis. Finally, the analytical method was
used to determine both antituberculosis drugs in incurred plasma samples of Tuberculosis patients. [-]
Publicat a
Microchemical Journal, 157, 2020.Proyecto de investigación
UJIB2-018-20, AICO/2017/063Drets d'accés
0026-265X/ © 2020 Elsevier B.V. All rights reserved.
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
Apareix a les col.leccions
- QFA_Articles [826]